Project

SAKK 17/18 Origin

Ongoing - recruitment closed · 2021 until 2024

Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Ongoing - recruitment closed
Start Date
2021
End Date
2024
Financing
SAKK
Study Design
Phase II
Keywords
Immunotherapy combining Gemcitabine with atezolizumab, advanced NSCLC, mesothelioma progressing, immune-checkpoint inhibitors or gemcitabine
Labels
lung cancer
Brief description/objective

A significant number of patients with malignant pleural mesothelioma (MPM) and non-small cell lung cancer (NSCLC) are not cured with available treatments and will eventually relapse. After relapse treatment options are limited. Preclinical in vitro studies have demon-strated a synergism of immunotherapy with PD(L)1- targeting monoclonal antibodies and gemcitabine ad-ministered in different tumors models and ongoing clin-ical studies showed encouraging results. This may represent a safe and effective therapy for patients who relapsed or did not respond to standard therapies.